Septerna names Rajiv Patni, M.D. as Chief Medical Officer

Septerna, Inc. announced on August 25, 2026 that it has appointed Rajiv Patni, M.D., as Chief Medical Officer.¹ According to the company's Form 8-K, the appointment was effective August 24, 2026, following Board approval.¹

Dr. Patni is described as a physician-scientist and biopharmaceutical executive with more than 25 years of experience leading research, development, regulatory, and medical affairs organizations.¹ Over that span, he has contributed to programs that resulted in 10 regulatory agency approvals or label expansions in the United States, Europe and additional markets.¹

Patni's most recent role was at Judo Bio, where he served as Chief Executive Officer.¹ Before that, he was Chief Research and Development Officer at Reata Pharmaceuticals.¹ Earlier in his career, he served as Chief Medical Officer at Global Blood Therapeutics, Portola Pharmaceuticals, Adamas Pharmaceuticals and Actelion Pharmaceuticals, companies that, together with Reata, were subsequently acquired.¹ He also led development teams at Pfizer and Roche Pharmaceuticals earlier in his career.¹ He currently serves as a director of BioXcel Therapeutics.¹

On education, Dr. Patni holds an M.D. from the Icahn School of Medicine at Mt. Sinai and completed his internal medicine residency and cardiology fellowship at the Albert Einstein College of Medicine.¹

Septerna describes itself as a clinical-stage biotechnology company with a team of GPCR experts and drug developers working to unlock the potential of GPCR therapies for patients with significant unmet needs.¹ The company said its proprietary Native Complex Platform has led to a pipeline of novel oral small molecule drug candidates across endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas, pursued both independently and with partners.¹